Advertisement
CHRS vs LCTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and LCTX is a StrongBuy.
CHRS in -9.79% downward trend, sliding for three consecutive days on November 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CHRS declined for three days, in 296 of 326 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 43 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.498). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LCTX in upward trend: price may jump up because it broke its lower Bollinger Band on November 13, 2026
LCTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where LCTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 159 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 66 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LCTX as a result. In 100 of 119 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for LCTX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
LCTX moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.498). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. LCTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CHRS | LCTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 93 | 73 | |
P/E GROWTH RATING 1..100 | 98 | 34 | |
SEASONALITY SCORE 1..100 | n/a | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LCTX's Valuation (26) in the null industry is somewhat better than the same rating for CHRS (67) in the Biotechnology industry. This means that LCTX’s stock grew somewhat faster than CHRS’s over the last 12 months.
LCTX's Profit vs Risk Rating (100) in the null industry is in the same range as CHRS (100) in the Biotechnology industry. This means that LCTX’s stock grew similarly to CHRS’s over the last 12 months.
LCTX's SMR Rating (98) in the null industry is in the same range as CHRS (99) in the Biotechnology industry. This means that LCTX’s stock grew similarly to CHRS’s over the last 12 months.
LCTX's Price Growth Rating (73) in the null industry is in the same range as CHRS (93) in the Biotechnology industry. This means that LCTX’s stock grew similarly to CHRS’s over the last 12 months.
LCTX's P/E Growth Rating (34) in the null industry is somewhat better than the same rating for CHRS (98) in the Biotechnology industry. This means that LCTX’s stock grew somewhat faster than CHRS’s over the last 12 months.
| CHRS | LCTX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 89% | N/A |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 83% |
| Momentum ODDS (%) | 3 days ago 89% | 3 days ago 84% |
| MACD ODDS (%) | 3 days ago 88% | 3 days ago 78% |
| TrendWeek ODDS (%) | 3 days ago 90% | 3 days ago 83% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 84% |
| Advances ODDS (%) | 7 days ago 76% | 7 days ago 76% |
| Declines ODDS (%) | 3 days ago 90% | 3 days ago 83% |
| BollingerBands ODDS (%) | 3 days ago 77% | 3 days ago 89% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CHRS’s FA Score shows that 0 FA rating(s) are green while LCTX’s FA Score has 1 green FA rating(s).
- CHRS’s FA Score: 0 green, 5 red.
- LCTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CHRS’s TA Score shows that 4 TA indicator(s) are bullish while LCTX’s TA Score has 4 bullish TA indicator(s).
- CHRS’s TA Score: 4 bullish, 4 bearish.
- LCTX’s TA Score: 4 bullish, 5 bearish.
Price Growth
CHRS (@Biotechnology) experienced а -31.75% price change this week, while LCTX (@Biotechnology) price change was -10.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
CHRS is expected to report earnings on Mar 15, 2027.
LCTX is expected to report earnings on Mar 11, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VABS | 23.73 | -0.02 | -0.06% |
| Virtus Newfleet Securitized Income ETF (VABS) | |||
| MYCK | 23.88 | -0.02 | -0.07% |
| State Street My2031 Corporate Bond ETF (MYCK) | |||
| FRA | 10.12 | -0.07 | -0.69% |
| Blackrock Floating Rate Income Strategies Fund | |||
| BUG | 44.83 | -0.32 | -0.71% |
| Global X Cybersecurity ETF (BUG) | |||
| AMPU | 1.17 | -0.15 | -11.03% |
| Defiance Daily Target 2X Long AMPX ETF (AMPU) | |||